Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind study of pimodivir plus standard therapy in high-risk outpatients with influenza A
CTR20192333Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pimodivir in Influenza A infection, sponsored by Janssen Pharmaceutical. Started Nov 2019; status: terminated.
02
Drugs
pimodivir
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on CTR20192333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192333.